{"id":406423,"date":"2020-12-30T02:12:57","date_gmt":"2020-12-30T07:12:57","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=406423"},"modified":"2020-12-30T02:12:57","modified_gmt":"2020-12-30T07:12:57","slug":"orexo-announces-new-us-patent-for-zubsolv","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/","title":{"rendered":"Orexo announces new US patent for ZUBSOLV\u00ae"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>UPPSALA, <span class=\"xn-location\">Sweden<\/span>, <span class=\"xn-chron\">Dec. 30, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Orexo AB (publ.),<b>\u00a0(STO:ORX) (OTCQX:ORXOY)<\/b> today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV\u00ae, Orexo&#8217;s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder. <\/p>\n<p>The new patent, US Patent No. 10,874,661, expires in <span class=\"xn-chron\">September 2032<\/span> and further strengthens the company&#8217;s intellectual property for ZUBSOLV\u00ae in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV\u00ae.<\/p>\n<p>\n        <b>Nikolaj S\u00f8rensen, President and CEO, said:<\/b> &#8220;I am pleased to announce that we have further enhanced our patent protection of ZUBSOLV\u00ae with a new patent granted in the US. Strong patent protection is the foundation on which we finance and develop new innovative products to the benefit of patients and society. We continue to obtain strong patent protection of our products, <\/p>\n<p \/>\n<p><i><i>and the quality of our patents was demonstrated in 2018 by the US Court of Appeals for the Federal Circuit when one of our ZUBSOLV\u00ae patents was found valid and infringed by a generic company. With this new patent we stand even stronger and are well positioned to continue to play an important role in helping patients suffering from opioid addiction.&#8221;<\/i><\/i><\/p>\n<p \/>\n<p><b>For further information, please contact:<\/b><\/p>\n<p><b>Orexo AB (publ.)<\/b><\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Nikolaj S\u00f8rensen, President and CEO<\/span><\/p>\n<\/td>\n<td class=\"prngen4\"><\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Lena Wange, IR &amp; Communications Director<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Tel: +46 (0)18\u00a0780 88 00<\/span><\/p>\n<\/td>\n<td class=\"prngen4\"><\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Tel: +46 (0)18\u00a0780 88 00<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Email: <b><a target=\"_blank\" href=\"mailto:ir@orexo.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\"><b>ir@orexo.com<\/b><\/a><\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen4\"><\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Email: <b><a target=\"_blank\" href=\"mailto:ir@orexo.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\"><b>ir@orexo.com<\/b><\/a><\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<p>About Orexo <\/p>\n<p \/>\n<p>Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the US market for buprenorphine\/naloxone products, where Orexo commercializes its lead product ZUBSOLV\u00ae for treatment of opioid use disorder. Total net sales for 2019 amounted to <span class=\"xn-money\">SEK 844.8 million<\/span> and the number of employees was 127. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as an ADR on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, <span class=\"xn-location\">Sweden<\/span>.<\/p>\n<p \/>\n<p>For more information about Orexo please visit, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023664-1&amp;h=607697213&amp;u=http%3A%2F%2Fwww.orexo.com%2F&amp;a=www.orexo.com\" rel=\"nofollow noopener noreferrer\">www.orexo.com<\/a>. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. <\/p>\n<p>The information was submitted for publication at <span class=\"xn-chron\">8 am CET<\/span>, on <span class=\"xn-chron\">December 30, 2020<\/span>. <\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023664-1&amp;h=2880176144&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023664-1&amp;h=4062579526&amp;u=https%3A%2F%2Fnews.cision.com%2Forexo%2Fr%2Forexo-announces-new-us-patent-for-zubsolv-%2Cc3262514&amp;a=https%3A%2F%2Fnews.cision.com%2Forexo%2Fr%2Forexo-announces-new-us-patent-for-zubsolv-%2Cc3262514\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/orexo\/r\/orexo-announces-new-us-patent-for-zubsolv-,c3262514<\/a><\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\"><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3023664-1&amp;h=1241127365&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F694%2F3262514%2F1354804.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F694%2F3262514%2F1354804.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/694\/3262514\/1354804.pdf<\/a><\/span><\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Orexo announces new US patent for ZUBSOLV\u00ae <\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO34907&amp;sd=2020-12-30\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/orexo-announces-new-us-patent-for-zubsolv-301199255.html\">http:\/\/www.prnewswire.com\/news-releases\/orexo-announces-new-us-patent-for-zubsolv-301199255.html<\/a><\/p>\n<p>SOURCE  Orexo<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO34907&amp;Transmission_Id=202012300209PR_NEWS_USPR_____IO34907&amp;DateId=20201230\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire UPPSALA, Sweden, Dec. 30, 2020 \/PRNewswire\/ &#8212;\u00a0Orexo AB (publ.),\u00a0(STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV\u00ae, Orexo&#8217;s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder. The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company&#8217;s intellectual property for ZUBSOLV\u00ae in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV\u00ae. Nikolaj S\u00f8rensen, President and CEO, said: &#8220;I am pleased to announce that we have further enhanced our patent protection of ZUBSOLV\u00ae with a new patent granted in the US. Strong patent protection is the foundation on which we finance and develop new &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Orexo announces new US patent for ZUBSOLV\u00ae&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-406423","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orexo announces new US patent for ZUBSOLV\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orexo announces new US patent for ZUBSOLV\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire UPPSALA, Sweden, Dec. 30, 2020 \/PRNewswire\/ &#8212;\u00a0Orexo AB (publ.),\u00a0(STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV\u00ae, Orexo&#8217;s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder. The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company&#8217;s intellectual property for ZUBSOLV\u00ae in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV\u00ae. Nikolaj S\u00f8rensen, President and CEO, said: &#8220;I am pleased to announce that we have further enhanced our patent protection of ZUBSOLV\u00ae with a new patent granted in the US. Strong patent protection is the foundation on which we finance and develop new &hellip; Continue reading &quot;Orexo announces new US patent for ZUBSOLV\u00ae&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-30T07:12:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO34907&amp;sd=2020-12-30\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Orexo announces new US patent for ZUBSOLV\u00ae\",\"datePublished\":\"2020-12-30T07:12:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/\"},\"wordCount\":433,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO34907&amp;sd=2020-12-30\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/\",\"name\":\"Orexo announces new US patent for ZUBSOLV\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO34907&amp;sd=2020-12-30\",\"datePublished\":\"2020-12-30T07:12:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO34907&amp;sd=2020-12-30\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO34907&amp;sd=2020-12-30\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orexo-announces-new-us-patent-for-zubsolv\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orexo announces new US patent for ZUBSOLV\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orexo announces new US patent for ZUBSOLV\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/","og_locale":"en_US","og_type":"article","og_title":"Orexo announces new US patent for ZUBSOLV\u00ae - Market Newsdesk","og_description":"PR Newswire UPPSALA, Sweden, Dec. 30, 2020 \/PRNewswire\/ &#8212;\u00a0Orexo AB (publ.),\u00a0(STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV\u00ae, Orexo&#8217;s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder. The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company&#8217;s intellectual property for ZUBSOLV\u00ae in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV\u00ae. Nikolaj S\u00f8rensen, President and CEO, said: &#8220;I am pleased to announce that we have further enhanced our patent protection of ZUBSOLV\u00ae with a new patent granted in the US. Strong patent protection is the foundation on which we finance and develop new &hellip; Continue reading \"Orexo announces new US patent for ZUBSOLV\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-30T07:12:57+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO34907&amp;sd=2020-12-30","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Orexo announces new US patent for ZUBSOLV\u00ae","datePublished":"2020-12-30T07:12:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/"},"wordCount":433,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO34907&amp;sd=2020-12-30","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/","name":"Orexo announces new US patent for ZUBSOLV\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO34907&amp;sd=2020-12-30","datePublished":"2020-12-30T07:12:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO34907&amp;sd=2020-12-30","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO34907&amp;sd=2020-12-30"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orexo-announces-new-us-patent-for-zubsolv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Orexo announces new US patent for ZUBSOLV\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=406423"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406423\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=406423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=406423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=406423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}